1400 Seaport Blvd, Building B
26 articles with HeartFlow
New JAMA Network Open Publication Demonstrates the Coronary CT- HeartFlow Analysis Pathway Is ‘Dominant’ Compared to Stress Testing in Cost-Effectiveness Analysis
HeartFlow, Inc., a leader in revolutionizing precision heartcare, announced that a new cost-effectiveness analysis found a diagnostic pathway which utilizes coronary computed tomography angiography with the HeartFlow FFRct Analysis to be “dominant” as compared to stress testing for assessing patients with coronary artery disease, the leading cause of death.
HeartFlow Applauds Healthcare Stakeholders’ Push for Change in How Coronary Artery Disease is First Diagnosed
Use of coronary CTA instead of stress tests alone results in increased early initiation of preventative therapy and 41% reduction in cardiac death and myocardial infarction
HeartFlow, Inc. today announced that it has obtained clearance from the U.S. Food and Drug Administration (FDA) for the HeartFlow Planner, a non-invasive, real-time virtual modeling tool for coronary artery disease (CAD) intervention.
NHS England to Extend Reimbursement for the HeartFlow Analysis Through Innovation and Technology Payment (ITP) Program
ITP Program extended in recognition of the positive impact of the HeartFlow Analysis on patient management, streamlining treatment strategies and reducing waiting lists
HeartFlow, Inc. today announced that it has named Dana G. Mead, Jr. as President and Chief Executive Officer (CEO).
Late-Breaking Data Reinforces How the HeartFlow Analysis Can Help Physicians Precisely Stratify Heart Disease Patients and Deliver More Personalized Care
One-year results from ADVANCE trial demonstrate how the HeartFlow Analysis can help identify lower-risk patients who can safely avoid invasive testing
HeartFlow, Inc., a medical technology company uniquely positioned at the intersection of advanced artificial intelligence (AI) capabilities and healthcare, today announced it has been named to Fast Company’s prestigious annual list of the World’s Most Innovative Companies for 2019.
HeartFlow, Inc. today announced the start of the Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization (PRECISE) trial. The first patient was enrolled by Michael C. Turner, M.D., at Imperial Health Cardiovascular Specialists in Lake Charles, LA.
HeartFlow Analysis to be covered by Japan’s health insurance system, making it more broadly available to patients with suspected coronary artery
So far in 2018, it’s been a good year for biotech initial public offerings (IPOs). According to a Crunchbase News article, in the second quarter of this year alone, there were at least 16 U.S. venture-backed biotech and healthcare IPOs—compared to only 11 tech IPOs in the same period.
Joint research in medical imaging and deep learning to help improve treatment planning for patients with heart disease
2/15/2018The company will use the cash to ramp up commercial expansion of the HeartFlow FFRct Analysis, continued technology innovation and additional clinical studies.
HeartFlow Announces More Than 185 Million Patients Have Access to Non-Invasive HeartFlow FFRct Analysis
HeartFlow, Inc. today announced that seven new commercial payers issued positive medical policies covering the use of the HeartFlow FFRct Analysis following a coronary computed tomography angiogram (CCTA).
HeartFlow Announces Decision by HCSC and Additional BlueCross BlueShield Companies to Issue New Positive Medical Policies for Non-Invasive HeartFlow FFRct Analysis
Beginning January 1, 2018, hospitals that are enrolled in Medicare and bill CMS will be able to submit claims for the HeartFlow FFRct Analysis for Medicare patients.
HeartFlow makes software that builds a 3D model of your heart’s arteries, based on CT scans.
HeartFlow Announces Decision by Centers for Medicare & Medicaid Services to Assign a New Technology Payment Classification to HeartFlow FFRct Analysis
Under the APC payment system, hospitals enrolled in Medicare that bill CMS for the HeartFlow FFRct Analysis for Medicare patients will be eligible for reimbursement at a rate of $1,450.50 for the technical component of the test.
HeartFlow Announces Positive Medical Coverage Decisions On Non-Invasive Heartflow FFRct Analysis From Anthem Blue Cross Blue Shield, Blue Shield Of California And Blue Cross And Blue Shield Of Alabama
HeartFlow Announces American Medical Association Issues Unique Category III CPT Codes For HeartFlow FFRct